Bajaj Healthcare Ltd
BAJAJHCAREBajaj Healthcare Ltd
BAJAJHCAREPrice Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
-43.89 | 4.48 | 0.22% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.35 | 6.54 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Bajaj Healthcare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of bulk drugs and pharmaceutical products. The Company's segments include manufacturing of Bulk Drugs, and Formulation and sale of medicines.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 223.22 | 233.04 | 329.18 | 371.14 | 416.54 | 663.89 | 681.33 | 647.39 | 482.11 | 487.33 | ||||||||||
Raw Materials | 128.77 | 131.50 | 215.43 | 245.33 | 268.32 | 377.19 | 409.91 | 393.84 | 264.43 | 458.43 | ||||||||||
Power & Fuel Cost | 14.12 | 16.79 | 19.81 | 21.83 | 24.24 | 24.96 | 31.83 | 37.69 | 31.47 | |||||||||||
Employee Cost | 16.93 | 19.57 | 21.65 | 24.62 | 28.18 | 34.55 | 41.11 | 42.32 | 43.85 | |||||||||||
Selling & Administrative Expenses | 6.01 | 5.68 | 5.68 | 7.31 | 8.00 | 12.91 | 14.86 | 14.86 | 16.21 | |||||||||||
Operating & Other expenses | 26.96 | 26.28 | 25.10 | 28.16 | 32.98 | 71.00 | 63.52 | 66.11 | 154.92 | |||||||||||
EBITDA | 30.43 | 33.22 | 41.51 | 43.89 | 54.82 | 143.28 | 120.10 | 92.57 | -28.77 | 28.90 | ||||||||||
Depreciation/Amortization | 9.29 | 11.35 | 11.08 | 11.41 | 12.12 | 16.12 | 17.64 | 17.21 | 27.62 | 28.04 | ||||||||||
PBIT | 21.14 | 21.87 | 30.43 | 32.48 | 42.70 | 127.16 | 102.46 | 75.36 | -56.39 | 0.86 | ||||||||||
Interest & Other Items | 7.64 | 8.20 | 7.73 | 8.32 | 6.63 | 8.34 | 12.78 | 17.68 | 29.75 | 29.36 | ||||||||||
PBT | 13.50 | 13.67 | 22.70 | 24.16 | 36.07 | 118.82 | 89.68 | 57.68 | -86.14 | -28.50 | ||||||||||
Taxes & Other Items | 5.29 | 5.87 | 7.50 | 7.86 | 10.82 | 35.71 | 18.30 | 14.65 | -2.35 | -0.07 | ||||||||||
Net Income | 8.21 | 7.80 | 15.20 | 16.30 | 25.25 | 83.11 | 71.38 | 43.03 | -83.79 | -28.43 | ||||||||||
EPS | 2.28 | 1.43 | 2.75 | 2.95 | 4.57 | 15.06 | 17.24 | 15.59 | -30.36 | -10.30 | ||||||||||
DPS | 0.00 | 0.00 | 0.25 | 0.00 | 0.00 | 1.38 | 1.50 | 1.00 | 1.00 | 1.00 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.09 | 0.00 | 0.00 | 0.09 | 0.09 | 0.06 | — | -0.10 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Bajaj Healthcare Ltd | -14.89 | 4.48 | 0.22% |
Sun Pharmaceutical Industries Ltd | 45.34 | 6.47 | 0.75% |
Cipla Ltd | 31.21 | 4.80 | 0.82% |
Torrent Pharmaceuticals Ltd | 65.38 | 15.80 | 0.88% |
Price Comparison
Compare BAJAJHCARE with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 8.55%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 1.06%
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 1.31%
Top 1 Mutual Funds holding Bajaj Healthcare Ltd
Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
HDFC Pharma and Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.0762% | Percentage of the fund’s portfolio invested in the stock 0.97% | Change in the portfolio weight of the stock over the last 3 months 0.97% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 28/37 (+9) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 23, 2024
Dividend/Share
₹1.00
Ex DateEx Date
Sep 23, 2024
Cash Dividend
Ex DateEx DateSep 22, 2023
Dividend/Share
₹1.00
Ex DateEx Date
Sep 22, 2023
Cash Dividend
Ex DateEx DateSep 22, 2022
Dividend/Share
₹1.50
Ex DateEx Date
Sep 22, 2022
Cash Dividend
Ex DateEx DateSep 28, 2021
Dividend/Share
₹0.50
Ex DateEx Date
Sep 28, 2021
Cash Dividend
Ex DateEx DateSep 28, 2021
Dividend/Share
₹0.50
Ex DateEx Date
Sep 28, 2021
Bajaj Healthcare has entered into a development and supply agreement for an Active Pharmaceutical Ingredient (API) with a European entity. This API after its development will be initially supplied in small quantities and will be used by the EU partner to carry out clinical trials for an alternative indication. Based on the outcome of these trials, the supplies will be done from the Company's FDA approved manufacturing facility situated at Savli, Vadodara.Powered by Capital Market - Live
After the development, the API will be initially supplied in small quantities and will be used by the EU partner to carry out clinical trials for an alternative indication. The trust reposed in the company by the EU partner for sourcing clinical trial quantities is a testimony of the company's development and manufacturing capabilities along with the good manufacturing practices (GMP) compliance at company's manufacturing units. Based on the outcome of these trials, the supplies will be done from the company's FDA approved manufacturing facility situated at Savli, Vadodara. Bajaj Healthcare a leading manufacturer of APIs, intermediates and formulations. It has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America. The company's standalone net profit jumped 14.1% to Rs 8.02 crore in Q1 FY25 as against 7.03 crore recorded in Q1 FY24. Revenue from operations increased 1.9% YoY to Rs 132.25 crore in Q1 FY25.Powered by Capital Market - Live
The Board of Bajaj Healthcare at its meeting held on 19 September 2024 has approved the allotment of 39,84,852 equity shares of the Company of face value of Rs. 5/- each fully paid at a price of Rs. 338/-, (including a premium of Rs. 333/- per equity share) aggregating to Rs. 1,34,68,79,976/-. The board has also approved allotment of 20,79,409 fully convertible warrants with each warrant convertible into or exchangeable for One (1) fully paid-up equity share of the Company of face value of Rs. 5/- each at an issue price of Rs. 338/-(including a premium of Rs. 333/-) per warrant, aggregating to Rs. 70,28,40,242/- to the Promoter, Promoter Group and Persons belonging to Non-Promoter category on Preferential Basis. Consequent to the aforesaid allotment of Equity Shares, the paid-up equity share capital of the Company stands increased to Rs. 15,79,16,260 comprising of 3,15,83,252 equity shares of the face value of Rs. 5/- each.Powered by Capital Market - Live
Bajaj Healthcare announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 19 September 2024.Powered by Capital Market - Live
Net profit of Bajaj Healthcare reported to Rs 7.13 crore in the quarter ended June 2024 as against net loss of Rs 48.21 crore during the previous quarter ended June 2023. Sales rose 1.93% to Rs 132.25 crore in the quarter ended June 2024 as against Rs 129.74 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales132.25129.74 2 OPM %18.5316.76 - PBDT16.9113.22 28 PBT10.186.91 47 NP7.13-48.21 LP Powered by Capital Market - Live
Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live
Bajaj Healthcare Shares Soar 16% On API Deals With U.K., EU Clients
Stocks to watch on June 30, 2023
Sensex dives over 500 points: Rs 1.25L cr investor wealth lost; KRBL, Rhi Magnesita & Campus Activewear down up to 9%
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 5.37%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.17% to 0.13%